CClinicalTrials.gg
Status unknownNCT04650061PIMAGASOXMEDUpdated Dec 2, 2020

PIMA - Individualized Adherence Improvement Plan

An interventional study of Motivational Interview (MI) & Adherence Follow-Up and Adherence Follow-Up in Sleep Apnea, Obstructive, sponsored by Air Liquide Healthcare Spain. Status unknown at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by Air Liquide Healthcare Spain · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Continuous positive airway pressure (CPAP) is the first-line treatment for sleep apnoea/hypopnoea syndrome (OSA). The aim of this study is to know the results in adherence to CPAP and health related outcomes in patients with OSA through a comprehensive and multidisciplinary program based on stratification and individualized care plans, including the motivational interview.

Methods: A multicenter randomized controlled trial (RCT) is designed. The control group will follow the usual treatment, while the intervention group (PIMA) will follow the treatment according to the stratification label based on a comprehensive assessment. This label determines a personalized treatment plan for each patient, which includes different channels (home, telephone, care center) and the use of the motivational interview in each of the interventions with the patient. The main outcome was adherence. Secondary outcomes were quality of life, emotional state, activities, social relationships, perceived competence and motivation.

Read the detailed description

The subjects enrolled in the study are required to have a diagnosis of OSA confirmed by sleep studies with polygraphy (PS) and / or polysomnography(PSG). Prior to enrolment in the study, all patients are informed in detail about the study and signed the consent form to participate. A randomisation process will follow using a random number generator in Statistical Package for the Social Sciences (SPSS) to systematically assign patients to one group or another, with allocation concealment. Responsible for randomization are prescribers.

The control group intervention. The patients will follow the standard of care, which consists of starting therapy in the home, where the nurse perform training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient is always visited at home or telephone, with a frequency established by the Portuguese Society of Sleep(Day 7, Day 21 and Day 180). The follow-up procedure consists of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, explanation of specific aspects).

The intervention group 'PIMA' (Personalized Adherence Improvement Plan, based on the Spanish acronym), starts the treatment with the educational and training program called MEntA (Motivational Interview for Adherence). MEntA intervention consists of one session lasting approximately 60 minutes, which is divided into two blocks: educational activity and training activity. In the first block, nurse explains the concepts of sleep apnoea and the symptoms, while a patient shows the CPAP treatment and how to optimize this to the fullest. This block is reinforced with documentation in hard copy and digital format. The second block on training activity was based on working with the treatment, equipment, safety, hygiene and advice. MEntA uses the MI to the treatment of OSA with CPAP. In fact, the nurse uses MI not only at the beginning of therapy, but also in every contact that the patient has with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc). For the PIMA group, the nurse was specifically trained to give this intervention to patients, including a training session with a clinical psychologist.

After the educational and training program, the nurse performs the stratification process to know a series of patient characteristics that will allow identifying the best care plan to obtain the best results in adherence and quality of life. The stratification labels that determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables.With the psychological and clinical variables, in this first visit, "predictive" information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence. Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Low or moderate adherence relative face plans are more intensive than high adherence relative care plans. In follow-up visits (whose frequency depends on the level of adherence), psychological and clinical variables are reviewed and the patient's adherence is added. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used with hours of compliance, the Apnea-hypoanea index(AHI) and air leak.

02

Conditions studied

  • Sleep Apnea, Obstructive
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Older than 18 years, diagnosis of OSA confirmed by sleep studies with polygraphy (PS) and / or polysomnography (PSG)

Exclusion criteria

Exclusion Criteria:

  • subjects with obesity-related hypoventilation, severe COPD (chronic obstructive pulmonary disease) , cognitive disorders and those unable to understand the consent to participate
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    PIMA Group

    1. MEntA: Educational \& Training Program 2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour) 3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support 4. Identification of Care plan and Schedule next visits 5. Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan

    Behavioral: Motivational Interview (MI) & Adherence Follow-Up

  • Active comparator
    Control

    1. Training program 2. Schedule next visits 3. Follow-up D21-D90-D120-D180 using the same process: visit at home or phone.

    Device: Adherence Follow-Up

Interventions

  • BehavioralMotivational Interview (MI) & Adherence Follow-Up

    With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.

  • DeviceAdherence Follow-Up

    The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.

05

What researchers measure

Primary outcomes

  1. Change in adherence in the first 6 months of treatment

    Number of hours using CPAP per night

    Time frame: Day 21, Day 90, Day 120, Day 180

  2. Change in somnolence in the first 6 months of treatment

    Residual sleepiness after use of CPAP. Epworth Test

    Time frame: Day 21, Day 90, Day 120, Day 180

  3. Change in perceived competence in the first 6 months of treatment

    Self-Efficacy in the CPAP treatment. Perceived Competence Evaluation Questionnaire

    Time frame: Day 21, Day 90, Day 120, Day 180

  4. Change in Apnea-hypoanea index in the first 6 months of treatment

    Number of apneas-hypoapneas per night

    Time frame: Day 21, Day 90, Day 120, Day 180

  5. Change in Air Leaks in the first 6 months of treatment

    Fly away through the suitcase adaptation of the mask. Measured in liters / per minute

    Time frame: Day 21, Day 90, Day 120, Day 180

Secondary outcomes

  1. Change in Quality of Life in the first 6 months of treatment

    Well-Being of the patient related to sleep apnea. Analogical Well-Being in Sleep Apnea Scale

    Time frame: Day 21, Day 90, Day 120, Day 180

  2. Change in Mood in the first 6 months of treatment

    Emotional status related to sleep apnea. Ad hoc question

    Time frame: Day 21, Day 90, Day 120, Day 180

  3. Change in Activities in the first 6 months of treatment

    Improving general activity after use CPAP. Ad hoc question

    Time frame: Day 21, Day 90, Day 120, Day 180

  4. Change in Social Relationships in the first 6 months of treatment

    Improving general social relations after use CPAP. Ad hoc question

    Time frame: Day 21, Day 90, Day 120, Day 180

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Publication of results in two phases: * National Congress in Portugal * Publication in Research Journal

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04650061
Lead sponsor
Air Liquide Healthcare Spain
Collaborators
Hospital Sao Joao, Hospital Pedro Hispano
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Oct 1, 2020
Primary completion
Jan 14, 2021 (estimated)
Completion
Jun 30, 2021 (estimated)
Last update
Dec 2, 2020

Study contacts

David Rudilla, PhD
Contact
david.rudilla@airliquide.com
+34667126630
Antonio Denis Ferreira
Contact
antoniod.ferreira@airliquide.com
+(351) 96240 62 00
David Rudilla, PhD
principal investigator · Air Liquide Healthcare Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion